On account of the pivotal trial[1] and of a subsequent randomized phase II study (M77001)[2], this monoclonal antibody was registered for the treatment of HER2-positive advanced breast cancer patients in combination with the taxanes paclitaxel and docetaxel. This evidence concerns the gene ERBB2 and breast cancer.